Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Medivation
Evaluate
January 11, 2017
JP Morgan day two roundup – all talk, very little action
October 17, 2016
M&A gives signs of reverting to the mean
October 07, 2016
Lively M&A scene keeps biotech shares buoyant in Q3
September 29, 2016
Esmo preview – Novel checkpoints add to the Parp showdown
September 26, 2016
No great disturbance for pharma’s biggest force
September 12, 2016
Raptor faces up to its new reality
September 09, 2016
Snippet roundup: Gilead’s Parp interest, Futura and Retrophin get data boost
September 07, 2016
How Gilead could go back to basics
August 26, 2016
Esmo preview – A Merck versus Bristol showdown
August 24, 2016
Few M&A teams venture beyond domestic borders
August 24, 2016
Committed seller could give Pfizer an antibiotic bargain
Load More
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics